Puma Biotechnology Q4 product revenue rises to $59.9 mln
Overview
Biopharmaceutical company's Q4 product revenue rises to $59.9 mln from NERLYNX sales
Adjusted EPS for Q4 was $0.30
Company anticipates key milestones for alisertib trials in 2026
Outlook
Puma forecasts 2026 revenue between $214 mln and $221 mln
Company expects 2026 net income between $10 mln and $13 mln
Puma anticipates interim data from ALISCA-Breast1 trial in Q2 2026
Result Drivers
NERLYNX SALES - Product revenue from NERLYNX increased to $59.9 mln in Q4 2025, up from $54.4 mln in Q4 2024
ROYALTY REVENUE - Royalty revenue rose significantly to $15.6 mln in Q4 2025 from $4.7 mln in Q4 2024
COST OF SALES - Decrease in cost of sales due to reduced product unit sales to sub-licensees, offset by higher domestic sales
Company press release: ID:nBwbhQRqka
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q4 Product Revenue |
| $59.90 mln |
|
Q4 Adjusted EPS | Beat | $0.30 | $0.23 (1 Analyst) |
Q4 EPS |
| $0.27 |
|
Q4 Adjusted Net Income | Beat | $15.10 mln | $11.60 mln (1 Analyst) |
Q4 Net Income |
| $13.40 mln |
|
Analyst Coverage
The one available analyst rating on the shares is "hold"
The average consensus recommendation for the pharmaceuticals peer group is "buy."
Wall Street's median 12-month price target for Puma Biotechnology Inc is $5.00, about 34.9% below its February 25 closing price of $7.68
The stock recently traded at 14 times the next 12-month earnings vs. a P/E of 15 three months ago
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
Related Articles
Tesla Steps Up China Market Promotions; Can EV Business Bottom Out and Rebound?
TradingKey - On February 26 local time, Tesla (TSLA) China announced that for orders placed by March 31, select models will be eligible for 7-year ultra-low interest and 5-year zero-interest financing plans, as well as insurance subsidies.
Paramount Offers High Price Again to Bid for Warner Bros., Netflix Acquisition Hits Twists and Turns.
TradingKey - Hollywood media group Warner Bros. (WBD) announced Tuesday that it has received a revised acquisition proposal from Paramount (PSKY), raising the offer from the previous $30 to $31 per share in cash. The Board of Directors stated that this new bid "is likely to constitute a superior proposal" to the current agreement with Netflix and noted that negotiations between the two parties are continuing. The existing deal with Netflix (NFLX) remains in effect, as the Warner Bros. Board has not yet formally designated the Paramount offer as the superior proposal.
Tesla Stock Outlook: Why 2026 Could Be the Year of the Tesla Robotaxi
TradingKey - The concept of autonomous mobility for Tesla(TSLA) has gone from a projection of the far away future to a vital part of its overall long-term growth strategy.
Will Bank of England Still Cut Rates in 2026? Falling Inflation Favors Loose Monetary Policy, Pound Exchange Rate May Struggle to Sustain Strength.
TradingKey - The outlook for the British Pound in 2026 is undoubtedly one of the most significant focal points for investors in the FX market. Following a structural shift in 2025 characterized by a "low start and high finish," GBP/USD successfully broke out of its two-year trading range and stabilized near 1.35 at year-end, laying the foundation for its performance in 2026.
Is SaaS Dead? The Truth Behind the Software Meltdown, the Missing Floor, and the Peak That’s Not Coming Back
TradingKey - A trillion dollars just vanished from software stocks—this piece breaks down who AI is really killing, who quietly benefits, and why cheap SaaS may be the biggest value trap of this cycle.
